TrialEuropean heart journal2022

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

HPS3/TIMI55-REVEAL Collaborative Group et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.